Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for GERN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -15.83M
March 31, 2026 -62.91M
December 31, 2025 -22.07M
September 30, 2025 -13.58M
June 30, 2025 -27.42M
March 31, 2025 -47.98M
December 31, 2024 -43.94M
September 30, 2024 -58.94M
June 30, 2024 -53.48M
March 31, 2024 -62.25M
December 31, 2023 -40.94M
September 30, 2023 -50.84M
June 30, 2023 -29.60M
March 31, 2023 -46.36M
December 31, 2022 -35.18M
September 30, 2022 -29.58M
June 30, 2022 -28.64M
March 31, 2022 -33.97M
December 31, 2021 -22.17M
September 30, 2021 -22.84M
June 30, 2021 -17.81M
March 31, 2021 -32.73M
December 31, 2020 -12.61M
September 30, 2020 -15.45M
June 30, 2020 -12.40M
Date Value
March 31, 2020 -26.19M
December 31, 2019 -10.37M
September 30, 2019 -11.98M
June 30, 2019 -8.745M
March 31, 2019 -12.74M
December 31, 2018 -3.01M
September 30, 2018 -6.136M
June 30, 2018 -4.495M
March 31, 2018 -7.368M
December 31, 2017 -4.387M
September 30, 2017 -4.424M
June 30, 2017 -4.438M
March 31, 2017 -7.307M
December 31, 2016 -0.602M
September 30, 2016 -6.553M
June 30, 2016 -5.636M
March 31, 2016 -5.578M
December 31, 2015 -5.251M
September 30, 2015 -4.905M
June 30, 2015 -6.335M
March 31, 2015 -7.705M
December 31, 2014 28.48M
September 30, 2014 -4.472M
June 30, 2014 -5.15M
March 31, 2014 -9.505M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Precigen, Inc. -17.81M
Editas Medicine, Inc. -29.57M
Agenus, Inc. -31.20M
Amgen, Inc. 4.002B
Anika Therapeutics, Inc. -0.684M